Sex-specific differences in Type 2 Diabetes Mellitus and dyslipidemia therapy: PPAR agonists.
Sex-specific differences in Type 2 Diabetes Mellitus and dyslipidemia therapy: PPAR agonists.
复制标题
DOI：
10.1007/978-3-642-30726-3_18
复制
发表时间：
2012-01-01
影响因子：
--
通讯作者：
Foryst-Ludwig, Anna
中科院分区：
文献类型：
--
作者：
Benz, Verena;Kintscher, Ulrich;Foryst-Ludwig, Anna
性别对肥胖、2型糖尿病（T2DM）和血脂异常发生的影响已得到充分证实，尽管这些差异背后的分子机制仍令人难以捉摸。过氧化物酶体增殖物激活受体（PPARs）的配体用作口服抗糖尿病药（PPARgamma激动剂：噻唑烷二酮类，TZD），或由于其降脂特性（PPARalpha激动剂：贝特类）而用于治疗血脂异常和心血管疾病，因为PPARs控制参与调节脂质和碳水化合物代谢的一组基因的转录。鉴于这些代谢紊乱的高患病率，因此广泛使用的PPAR激动剂，本审查将讨论不同方面的性别特异性差异，在使用这些组的PPAR配体的抗肥胖治疗。
The influence of sex on the development of obesity, Type 2 Diabetes Mellitus (T2DM), and dyslipidemia is well documented, although the molecular mechanism underlying those differences reminds elusive. Ligands of peroxisome proliferator-activated receptors (PPARs) are used as oral antidiabetics (PPARgamma agonists: thiazolidinediones, TZDs), or for the treatment of dyslipidemia and cardiovascular diseases, due to their lipid-lowering properties (PPARalpha agonists: fibrates), as PPARs control transcription of a set of genes involved in the regulation of lipid and carbohydrate metabolism. Given a high prevalence of those metabolic disorders, and thus a broad use of PPAR agonists, the present review will discuss distinct aspects of sex-specific differences in antiobesity treatment using those groups of PPAR ligands.